Bendroflumethiazide: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Ammu Susheela (talk | contribs)
nocaptcha, Administrators
14,466 edits
No edit summary
Gerald Chi- (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, oversight, smwadministrator, Administrators, Widget editors
7,699 edits
mNo edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{Drugbox
|authorTag=<!--Overview-->
| Watchedfields = changed
|aOrAn=a
| verifiedrevid = 459531641
|hasBlackBoxWarning=Yes
| IUPAC_name = 3-Benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2''H''-1,2,4- benzothiadiazine-7-sulfonamide
|adverseReactions=<!--Black Box Warning-->
| image = Bendroflumethiazide.svg
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| image2 = Bendroflumethiazide-3D-vdW.png
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|CDI|bendroflumethiazide}}
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = Risk neonatal [[thrombocytopenia]] in 3rd trimester<ref>[[British National Formulary|BNF]] '''45''' March 2003</ref>
| legal_AU = 
| legal_CA = 
| legal_UK = POM
| legal_US = 
| legal_status = 
| routes_of_administration = Oral


<!--Adult Indications and Dosage-->
<!--Pharmacokinetic data-->
| bioavailability = 100%
| protein_bound = 96%
| metabolism = extensive
| elimination_half-life = 3-4 hours<ref>{{cite book | editor = Ed. Sean C. Sweetman | title = [[Martindale: The complete drug reference]] | edition = 33 | publisher = Pharmaceutical Press}}</ref>


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--Identifiers-->
|fdaLIADAdult======Condition1=====
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 73-48-3
| ATC_prefix = C03
| ATC_suffix = AA01
| ATC_supplemental = 
| PubChem = 2315
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00436
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2225
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5Q52X6ICJI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00650
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3013
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1684


* Dosing Information
<!--Chemical data-->
 
| C=15 | H=14 | F=3 | N=3 | O=4 | S=2
:* Dosage
| molecular_weight = 421.415 g/mol
 
| smiles = FC(F)(F)c3c(cc1c(NC(NS1(=O)=O)Cc2ccccc2)c3)S(=O)(=O)N
=====Condition2=====
| InChI = 1/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
 
| InChIKey = HDWIHXWEUNVBIY-UHFFFAOYAU
* Dosing Information
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
 
| StdInChI = 1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
:* Dosage
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
 
| StdInChIKey = HDWIHXWEUNVBIY-UHFFFAOYSA-N
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Condition1
 
<!--Warnings-->
|warnings=* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Oral
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose====Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
 
<!--Structure-->
|structure=*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title =  | url = }}</ref>
 
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date = }}</ref>
 
<!--Drug Shortage Status-->
|drugShortage=
}}
}}
{{PillImage
__NOTOC__
|fileName=No image.jpg
{{SI}}
}}
{{CMG}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->
 


==Overview==
'''Bendroflumethiazide''' ([[International Nonproprietary Name|INN]]), formerly '''bendrofluazide''' ([[British Approved Name|BAN]]), trade name '''Aprinox''', is a [[thiazide]] [[diuretic]] used to treat [[hypertension]].


<!--Label Display Image-->
Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the [[distal convoluted tubule]] (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild [[heart failure]] although [[loop diuretic]]s are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to [[vasodilation]]).


Common adverse effects:{{medcn|date=September 2014}}


* [[Orthostatic hypotension|postural hypotension]]
* [[hyponatraemia]], [[hypokalaemia]], [[hypercalcaemia]]
* [[gout]]
* impaired glucose tolerance
* [[impotence]]


Rare adverse effects:{{medcn|date=September 2014}}


* [[thrombocytopenia]]
* [[agranulocytosis]]
* [[photosensitivity rash]]
* [[pancreatitis]]


<!--Category-->
==References==
{{reflist|2}}


{{Symporter inhibitors}}
{{Diuretics}}
[[Category:Drug]]
[[Category:Drug]]
[[Category:Carbonic anhydrase inhibitors]]
[[Category:Organofluorides]]
[[Category:Thiazides]]

Revision as of 03:19, 2 May 2015

Bendroflumethiazide
File:Bendroflumethiazide.svg
Clinical data
AHFS/Drugs.comConsumer Drug Information
Pregnancy
category
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability100%
Protein binding96%
Metabolismextensive
Elimination half-life3-4 hours[2]
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H14F3N3O4S2
Molar mass421.415 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Bendroflumethiazide

Articles

Most recent articles on Bendroflumethiazide

Most cited articles on Bendroflumethiazide

Review articles on Bendroflumethiazide

Articles on Bendroflumethiazide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bendroflumethiazide

Images of Bendroflumethiazide

Photos of Bendroflumethiazide

Podcasts & MP3s on Bendroflumethiazide

Videos on Bendroflumethiazide

Evidence Based Medicine

Cochrane Collaboration on Bendroflumethiazide

Bandolier on Bendroflumethiazide

TRIP on Bendroflumethiazide

Clinical Trials

Ongoing Trials on Bendroflumethiazide at Clinical Trials.gov

Trial results on Bendroflumethiazide

Clinical Trials on Bendroflumethiazide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bendroflumethiazide

NICE Guidance on Bendroflumethiazide

NHS PRODIGY Guidance

FDA on Bendroflumethiazide

CDC on Bendroflumethiazide

Books

Books on Bendroflumethiazide

News

Bendroflumethiazide in the news

Be alerted to news on Bendroflumethiazide

News trends on Bendroflumethiazide

Commentary

Blogs on Bendroflumethiazide

Definitions

Definitions of Bendroflumethiazide

Patient Resources / Community

Patient resources on Bendroflumethiazide

Discussion groups on Bendroflumethiazide

Patient Handouts on Bendroflumethiazide

Directions to Hospitals Treating Bendroflumethiazide

Risk calculators and risk factors for Bendroflumethiazide

Healthcare Provider Resources

Symptoms of Bendroflumethiazide

Causes & Risk Factors for Bendroflumethiazide

Diagnostic studies for Bendroflumethiazide

Treatment of Bendroflumethiazide

Continuing Medical Education (CME)

CME Programs on Bendroflumethiazide

International

Bendroflumethiazide en Espanol

Bendroflumethiazide en Francais

Business

Bendroflumethiazide in the Marketplace

Patents on Bendroflumethiazide

Experimental / Informatics

List of terms related to Bendroflumethiazide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bendroflumethiazide (INN), formerly bendrofluazide (BAN), trade name Aprinox, is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

Common adverse effects:Template:Medcn

Rare adverse effects:Template:Medcn

References

  1. ↑ BNF 45 March 2003
  2. ↑ Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.

Template:Symporter inhibitors Template:Diuretics

Retrieved from "https://www.wikidoc.org/index.php?title=Bendroflumethiazide&oldid=1093545"